PREDICTIVE BIOMARKER FOR HYPOXIA-ACTIVATED PRODRUG THERAPY
- 专利权人:
- Brian A. Elenbaas
- 发明人:
- Brian A. Elenbaas,Antonio Gualberto,Charles Praray Hart
- 申请号：
- US15528067
- 公开号：
- US20180334716A1
- 申请日:
- 2015.11.18
- 申请国别(地区):
- US
- 年份:
- 2018
- 代理人:
- 摘要：
- Enolase levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of hypoxia-activated achiral phosphoramide mustards.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING ENOBLOCK AS ACTIVE INGREDIENT
- PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING ENOBLOCK AS ACTIVE INGREDIENT
- ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY
- ALPHA-ENOLASE SPECIFIC ANTIBODIES AND METHODS OF USES IN CANCER THERAPY
- Metabolic gene, enzyme, and flux targets for cancer therapy
